
Opinion|Videos|July 24, 2024
Future Implications of Combination Regimens and Treatment Duration in CLL/SLL
Author(s)Mazyar Shadman, MD, MPH
Following recent updates from the SEQUOIA Arm D and CAPTIVATE studies, Mazyar Shadman, MD, MPH, discusses the future implications of fixed-duration therapy for patients with CLL/SLL.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What are the future implications of fixed-duration therapy for patients with CLL/SLL?
- What are the implications of the SEQUOIA Arm D and CAPTIVATE studies for this therapeutic approach?
- What are the implications of the SEQUOIA Arm D and CAPTIVATE studies for this therapeutic approach?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
4
Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma
5



















